In the May 17 issue of the Journal of the American Medical Association, a new study found that clinical drug trials funded by drug companies and other for-profit entities were more likely to report positive findings than similar trials funded by nonprofit groups. With pressure being put on the FDA to ensure safety of the public (their mandate for those who believe it's just to capitulate to drug company requests), studies like this show just how important this is, and how much the FDA is failing the American Public in their effort to boost up this multi-trillion dollar sector of the economy.
Hopefully, more studies like this will force groups like the FDA to support and work for We The People instead of their favorite lobbyists.
http://jama.ama-assn.org/cgi/content/short/295/19/2270
An analysis of trials for Avandia concluded that the drug might significantly increase the risk of heart attacks.
An analysis of trials for Avandia concluded that the drug might significantly increase the risk of heart attacks.
Partners in the UK-based innovative alternative health company, Sweet Cures of York, are leading a demand for drug trials to also test against natural remedies, both new and traditional, as well as placebo. The information revealed would be invaluable to our sum of knowledge about natural remedies, not only about what works, but about what doesn't work. New drugs are often arrived at by extracting active ingredients from plants that have been traditionally used as remedies. Pharmaceutical companies should have to prove that they can do better than the original plant. (PRWeb Apr 2, 2008)
Read the full story at http://www.prweb.com/releases/2008/04/prweb820814.htm
Partners in the UK-based innovative alternative health company, Sweet Cures of York, are leading a demand for drug trials to also test against natural remedies, both new and traditional, as well as placebo. The information revealed would be invaluable to our sum of knowledge about natural remedies, not only about what works, but about what doesn't work. New drugs are often arrived at by extracting active ingredients from plants that have been traditionally used as remedies. Pharmaceutical companies should have to prove that they can do better than the original plant. (PRWeb Apr 2, 2008)
Read the full story at http://www.prweb.com/releases/2008/04/prweb820814.htm
Two targeted medications designed to treat an aggressive form
of breast cancer are being tested in a new study involving 8,000
participants in 50 countries across six continents — a clinical
trial that investigators hope will provide a new model for global
cancer research. This trial, dubbed ALTTO (Adjuvant Lapatinib and-or
Trastuzumab Treatment Optimization study), will be one of the first
global initiatives in which two large, academic breast cancer research
networks covering different parts of the world have jointly developed
a study in which all care and data collection are standardized,
regardless of where patients are treated. The networks are The
Breast Cancer Intergroup of North America (TBCI), based in the
United States, and the Breast International Group (BIG) in Brussels,
Belgium. TBCI consists of six National Cancer Institute (NCI)-funded
clinical trials cooperative groups. NCI is part of the National
Institutes of Health.
Two new clinical trials presented by Calpis Co., Ltd. at the American Society of Hypertension (ASH) Twenty-Third Annual Scientific Meeting and Exposition (ASH 2008) in New Orleans show that the milk-derived dietary supplement AmealPeptide® reduces blood pressure in hypertensive patients. The studies, called AHEAD (Achieve Hypertension Efficacy with AmealPeptide® Dietary Supplement) II, and the PROBE (A Prospective, Two-phase Randomized, Open-Label, Blinded End-Point) Dose Response Study confirmed the safety and efficacy of AmealPeptide® for patients with Stage I and Stage II hypertension. (PRWeb May 16, 2008)
Read the full story at http://www.prweb.com/releases/blood_pressure/calpis/prweb949954.htm
The National Eye Institute (NEI) of the National Institutes of
Health (NIH) announces the start of a multicenter clinical trial
to compare the relative safety and effectiveness of two drugs currently
used to treat advanced age-related macular degeneration (AMD).
The two drugs are Lucentis (ranibizumab) and Avastin (bevacizumab).
The National Eye Institute (NEI) of the National Institutes of
Health (NIH) announces the start of a multicenter clinical trial
to compare the relative safety and effectiveness of two drugs currently
used to treat advanced age-related macular degeneration (AMD).
The two drugs are Lucentis (ranibizumab) and Avastin (bevacizumab).
